We are a clinical-stage biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer. We have industry-leading technology in two cell types, each with broad potential applicability: (1) oligodendrocyte progenitor cells, which become oligodendrocytes that have the potential to remyelinate axons within the central nervous system and perform other restorative functions, and (2) antigen-presenting dendritic cells, which train T-cells in the immune system to attack and destroy solid or liquid tumor cells across multiple types of cancer.
Company profile
Website
CEO
Michael H. Mulroy
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Latest filings (excl ownership)
15-12B
Securities registration termination
20 Mar 19
EFFECT
Notice of effectiveness
20 Mar 19
EFFECT
Notice of effectiveness
20 Mar 19
EFFECT
Notice of effectiveness
20 Mar 19
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Mar 19
POS AM
Prospectus update (post-effective amendment)
14 Mar 19
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Mar 19
POS AM
Prospectus update (post-effective amendment)
14 Mar 19
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Mar 19
POS AM
Prospectus update (post-effective amendment)
14 Mar 19
Latest ownership filings
4
NEAL C BRADSHER
12 Mar 19
SC 13D/A
Asterias Biotherapeutics, Inc.
12 Mar 19
SC 13D/A
Asterias Biotherapeutics, Inc.
12 Mar 19
4
Edward Wirth
5 Mar 19
4
Michael H. Mulroy
5 Mar 19
4
Ryan Daniel Chavez
5 Mar 19
4
Ryan Daniel Chavez
4 Jan 19
4
Edward Wirth
4 Jan 19
SC 13D/A
Asterias Biotherapeutics, Inc.
8 Nov 18
4
Michael H. Mulroy
29 Aug 18
Institutional ownership, Q4 2020
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
IFP Advisors | 0.00 | $0.00 |